Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment

European Journal of Dermatology

Volumn 20, Issue 1, 2010, Pages 62-67

  Schäfer, Ines ^a   Hacker, Jana ^a   Rustenbach, Stephan Jeff ^a   Radtke, Marc ^a   Franzke, Nadine ^a   Augustin, Matthias ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

DLQI; PASI; Patient benefit; Patient reported outcomes; Psoriasis vulgaris

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; OUTPATIENT; PATIENT SATISFACTION; PROSPECTIVE STUDY; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; TREATMENT OUTCOME;

FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE;

EID: 76749144577     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.0815     Document Type: Article

References (30)

1. Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008; 159 (Suppl 2): 2-9.
2. van de Kerkhof PC. Options for the treatment of psoriasis: a multifactorial approach. Clin Dermatol 2008; 26: 419-23.
3. Ortonne JP. What are objectives of moderate to severe psoriasis treatment? Ann Dermatol Venereol 2008; 135 (Suppl 5): S281-4.
4. Augustin M, Lange S, Wenninger K, Seidenglanz K, Amon U, Zschocke I. Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system. Eur J Dermatol 2004; 14: 107-13.
5. Boehncke WH, Adebajo A, Cauli A, Nash P, Salvarani C, Kavanaugh AF. Initiative for quality in psoriasis and psoriatic arthritis. J Rheumatol 2008; 35: 1431-3.
6. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007; 5: 1-119.
7. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, et al. Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 2004; 151 (Suppl 69): 3-17.
8. Callen JP, Krueger GG, Lebwohl M, McBurney EI, Mease P, Menter A, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003; 49: 897-9.
9. Reich K, Griffiths CE. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res 2008; 300: 537-44.
10. Canpolat F, Cemil BC, Eskioǧlu F, Akis HK. Is facial involvement a sign of severe psoriasis? Eur J Dermatol 2008; 18: 169-71.
11. Krueger G, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Arch Dermatol 2001; 137: 280-4.
12. Mease PJ, Menter MA. Quality of life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006; 54: 685-704.
13. Consoli SM, Rolhion S, Martin C, et al. Low levels of emotional awareness predict a better response to dermatological treatment in patients with psoriasis. Dermatology 2006; 212: 128-36.
14. Zschocke I, Hammelmann U, Augustin M. Therapeutic benefits in dermatological therapy. Evaluation of therapy from the physician's und patient's perspective in psoriasis and atopic dermatitis. Hautarzt 2005; 56: 839-46.
15. Grob JJ. Why are quality of life instruments not recognized as reference measures in therapeutic trials of chronic skin disorders? J Invest Dermatol 2007; 127: 2315-22.
16. Touw CR, Hakaart-van-Roijen L, Verboom P, Rutten FFH, Finlay A. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporine. Br J Dermatol 2001; 144: 967-72.
17. Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and healthrelated quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008; 216: 260-70.
18. Dijkers MP. Individualization in quality of life measurement: instruments and approaches. Arch Phys Med Rehabil 2003; 84 (4 Suppl 2): S3-14.
19. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
20. Augustin M, Gajur A, Reich C, Rustenbach S, Schaefer I. Benefit evaluation in vitiligo treatment: Development and validation of a patient-defined outcomes questionnaire. Dermatology 2008; 217: 101-6.
21. Augustin M, Reich C, Schaefer I, Zschocke I, Rustenbach SJ. Development and validation of a new instrument for the assessment of patient-defined benefit in the treatment of acne. J Dtsch Dermatol Ges 2008; 6: 113-20.
22. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6.
23. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36: 551-9.
24. Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol 2004; 151: 381-7.
25. van de Kerkhof PC, Kragballe K, Austad J, Berth-Jones J, Cambazard F, de la Brassinne M, et al. Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity. Eur J Dermatol 2006; 16: 167-71.
26. Augustin M, Reich K, Reich C, Purwins S, Jeff Rustenbach S, Schäfer I, et al. Quality of psoriasis care in Germany - results of the national study PsoHealth 2007. J Dtsch Dermatol Ges 2008; 6: 640-5.
27. Delfino Jr M, Holt EW, Taylor CR, Wittenberg E, Qureshi AA. Willingness-to-pay stated preferences for 8 health-related qualityof-life domains in psoriasis: A pilot study. J Am Acad Dermatol 2008; 59: 439-47.
28. Salek MS, Finlay AY, Luscombe DK, Allen BR, Berth-Jones J, Camp RD, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial. Br J Dermatol 1993; 129: 422-30.
29. Demircay Z, Seckin D, Senol A, Demir F. Patient's perspective: an important issue not to be overlooked in assessing acne severity. Eur J Dermatol 2008; 18: 181-4.
30. Feldman SR, Menter A, Koo JY. Improved health related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004; 150: 317-26.